Evidence map›Paper›PMID 41159102›Full record

ArticleMolecular therapy. Oncology2025

GPC2-CAR T cells have potent preclinical activity against orthotopic medulloblastoma xenografts.

Reona Okada, Mia Fanuzzi, Constanza Rodriguez, Jangsuk Oh, Adhithi Sreenivasan, Hannah G Stack, Mariela Puebla, Ira Phadke, Allison P Cole, Shanshan Bradford and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Reona OkadaPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Mia FanuzziPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Constanza RodriguezPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jangsuk OhPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Adhithi SreenivasanPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Hannah G StackPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Mariela PueblaPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Ira PhadkePediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Allison P ColePediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Shanshan BradfordComputational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Michael C KellySingle Cell Analysis Facility, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Haiyan LeiPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Mitchell HoLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Jennifer A CotterDepartment of Pathology & Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA.
Carol J ThielePediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Xiyuan ZhangPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Anandani NellanPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Rosa NguyenPediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medulloblastoma (MB) is the most common malignant brain tumor in children. Patients with group 3 and 4 MB have poor clinical outcomes, underscoring the urgent need for new therapies. Glypican-2 (GPC2) is a recently discovered oncofetal antigen. Given its expression in brain tumors, we evaluated the preclinical activity of our GPC2-chimeric antigen receptor (CAR) against MB and compared it to two existing CARs targeting GD2 and B7-H3. Gene expression analysis of publicly available datasets was performed and validated with immunohistochemistry staining of patient samples. The MB cell line D283 and a newly generated cell line patient-derived xenograft, MAF1433, were used. Cytokine bead assays and single-cell RNA sequencing (scRNA-seq) were used for mechanistic studies. MB patient samples express up to moderate levels of GPC2. GPC2-CARs lead to significant

Indexed as

CAR T cellsglypicanGPC2immunotherapymedulloblastomaMT: Special Issue - Advancements in pediatric cancer therapyoncofetal antigenpediatric oncology

Identifiers

PMID41159102
PMCPMC12554907

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.